Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2022, provides an overview of the Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline landscape.

Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 10, 17, 2, 76, 33 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 14, 12 and 6 molecules, respectively.

Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Respiratory Syncytial Virus (RSV) Infections – Overview
Respiratory Syncytial Virus (RSV) Infections – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Respiratory Syncytial Virus (RSV) Infections – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Respiratory Syncytial Virus (RSV) Infections – Companies Involved in Therapeutics Development
Abhelix LLC
Abivax SA
ADMA Biologics Inc
Advac LLC
Advagene Biopharma Co Ltd
AIM Vaccine Co Ltd
Airway Therapeutics Inc
AlloVir Inc
Anima Biotech Inc
Aposense Ltd
Aridis Pharmaceuticals Inc
Artificial Cell Technologies Inc
AstraZeneca Plc
Atea Pharmaceuticals Inc
Atriva Therapeutics GmbH
Auro Vaccines LLC
AVM Biotechnology LLC
Bavarian Nordic AS
Beijing Advaccine Biotechnology Company Ltd
BioComo Inc
Biological E Ltd
Blue Lake Biotechnology Inc
BlueWillow Biologics Inc
BravoVax Co Ltd
Calder Biosciences Inc
Celestial Therapeutics Inc
Changchun Bcht Biotechnology Co Ltd
Chengdu Aoda Biotechnology Co Ltd
Chongqing Zhifei Biological Products Co Ltd
Cidara Therapeutics Inc
Clover Biopharmaceuticals Ltd
Codagenix Inc
ConserV Bioscience Ltd
Curevac NV
CyanVac LLC
Daiichi Sankyo Co Ltd
Enanta Pharmaceuticals Inc
Enyo Pharma SA
Esperovax Inc
Eucure (Beijing) Biopharma Co Ltd
Exopharm Ltd
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
GSK plc
HanaVax Inc
Heartland Vaccines LLC
iBio Inc
Icosavax Inc
IDBiologics Inc
ILiAD Biotechnologies LLC
Immunwork Inc
Imophoron Ltd
IMV Inc
Inhalon Biopharma Inc
Inovio Pharmaceuticals Inc
Intravacc BV
Johnson & Johnson
KARE Biosciences Inc
Karyopharm Therapeutics Inc
Kidswell Bio Corp
Mapp Biopharmaceutical Inc
Meissa Vaccines Inc
Merck & Co Inc
MicroQuin Ltd
Moderna Inc
Navigen Inc
NeuClone Pty Ltd
Neuracle Science Co Ltd
Novavax Inc
Oita University Institute of Advanced Medicine Inc
Pfizer Inc
Pinetree Therapeutics Inc
Pneumagen Ltd
Poolbeg Pharma Plc
Prime Vector Technologies GmbH
Primmune Therapeutics Inc
Prosit Sole Biotechnology (Beijing) Co Ltd
ReAlta Life Sciences Inc
Revelation Biosciences Inc
Riboscience LLC
Romark Laboratories LC
Ruiyang (Suzhou) Biotechnology Co Ltd
Sagimet Biosciences Inc
Sanofi
Sciwind Biosciences Co Ltd
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Ark Biopharmaceutical Co Ltd
Shionogi & Co Ltd
Sigmovir Biosystems Inc
Signia Therapeutics
SK Bioscience Ltd
Taisho Pharmaceutical Holdings Co Ltd
TechnoVax Inc
Trimunocor Ltd
TrippBio Inc
Uvax Bio LLC
Vault Pharma Inc
Vaxart Inc
Vaxxel SAS
Vicebio Ltd
Vir Biotechnology Inc
Viramatix Sdn Bhd
Viravaxx AG
Virometix AG
Visterra Inc
VLP Biotech Inc
X4 Pharmaceuticals Inc
XBiotech Inc
Zhuhai Trinomab Biotechnology Co Ltd
Respiratory Syncytial Virus (RSV) Infections – Drug Profiles
(human metapneumovirus + human respiratory syncytial virus) (bivalent) vaccine – Drug Profile
(human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine – Drug Profile
(influenza (virus like particle) + respiratory syncytial virus) vaccine – Drug Profile
(influenza + Coronavirus Disease 2019 (COVID-19) + respiratory syncytial virus) vaccine – Drug Profile
(pertussis + respiratory syncytial virus) vaccine – Drug Profile
ABX-196 – Drug Profile
ADV-110 – Drug Profile
AK-0529 – Drug Profile
AK-0610 – Drug Profile
AK-0611 – Drug Profile
AK-0702 – Drug Profile
ALVR-106 – Drug Profile
Antisense RNAi Oligonucleotide for Respiratory Syncytial Virus (RSV) Infections – Drug Profile
AR-201 – Drug Profile
ASN-500 – Drug Profile
AVG-388 – Drug Profile
AZ-27 – Drug Profile
B-1402 – Drug Profile
BC-0005 – Drug Profile
BC-0335 – Drug Profile
BL-200 – Drug Profile
BLB-201 – Drug Profile
CAL-100 – Drug Profile
CDX-RSV – Drug Profile
clesrovimab – Drug Profile
CR-32T – Drug Profile
CT-02 – Drug Profile
dexamethasone sodium phosphate – Drug Profile
DPX-RSV – Drug Profile
Drugs for Respiratory Syncytial Virus – Drug Profile
Drugs for Viral Infections – Drug Profile
DSCav-1 – Drug Profile
EDP-323 – Drug Profile
EDP-938 – Drug Profile
Fusion Proteins for Coronavirus Disease 2019 (COVID-19) and Respiratory Syncytial Virus (RSV) Infections – Drug Profile
GSK-3844766A – Drug Profile
GSK-3888550A – Drug Profile
HEVS-124 – Drug Profile
IB-004R – Drug Profile
immune globulin (human) – Drug Profile
infectious disease vaccine – Drug Profile
IVX-121 – Drug Profile
IVXA-12 – Drug Profile
JNJ-64213175 – Drug Profile
JNJ-64400141 – Drug Profile
JNJ-7184 – Drug Profile
JNJ-78991172 – Drug Profile
JNJ-86051823 – Drug Profile
MM-002 – Drug Profile
MM-004 – Drug Profile
molnupiravir – Drug Profile
Monoclonal Antibodies for Respiratory Syncytial Virus (RSV) Infections – Drug Profile
Monoclonal Antibody for Respiratory Syncytial Virus – Drug Profile
Monoclonal Antibody for Respiratory Syncytial Virus Infections – Drug Profile
Monoclonal Antibody to Inhibit RSV F Protein for Respiratory Syncytial Virus Infections – Drug Profile
MPE-8 – Drug Profile
MRIRSM-01 – Drug Profile
MRKV-171 – Drug Profile
mRNA-1230 – Drug Profile
mRNA-1345 – Drug Profile
mRNA-1365 – Drug Profile
MV-012968 – Drug Profile
MVA-BN RSV – Drug Profile
Neumifil – Drug Profile
nirsevimab – Drug Profile
nitazoxanide CR – Drug Profile
P-220241 – Drug Profile
palivizumab biobetter – Drug Profile
palivizumab biosimilar – Drug Profile
pertussis [strain BPZE1] vaccine – Drug Profile
PF-06928316 – Drug Profile
PF-07923567 – Drug Profile
POLB-002 – Drug Profile
Polysaccharides for Viral Infections – Drug Profile
Product Candidates – Drug Profile
Protein for Respiratory Syncytial Virus Infection – Drug Profile
PRTX-007 – Drug Profile
PSP-008 – Drug Profile
ramatroban – Drug Profile
RB-0026 – Drug Profile
RBS-3149 – Drug Profile
Recombinant Protein for Infectious Disease and Oncology – Drug Profile
Recombinant Protein for RSV Infections – Drug Profile
Recombinant Surfactant Associated Protein D Replacement for SARS and RSV Infections – Drug Profile
respiratory syncytial virus (virus like particle) vaccine – Drug Profile
respiratory syncytial virus (virus like particle) vaccines – Drug Profile
respiratory syncytial virus (virus like particles) vaccine – Drug Profile
respiratory syncytial virus [strain 98-25147-X] vaccine – Drug Profile
respiratory syncytial virus [strain A/Maryland/001/11] vaccine – Drug Profile
respiratory syncytial virus vaccine – Drug Profile
respiratory syncytial virus vaccine 1 – Drug Profile
respiratory syncytial virus vaccine 2 – Drug Profile
respiratory syncytial virus vaccine 3 – Drug Profile
respiratory syncytial virus vaccine 4 – Drug Profile
respiratory syncytial virus vaccine 5 – Drug Profile
respiratory syncytial virus vaccine 6 – Drug Profile
respiratory syncytial virus vaccine 7 – Drug Profile
respiratory syncytial virus vaccines – Drug Profile
REVTx-99 – Drug Profile
rilematovir – Drug Profile
RLS-0071 – Drug Profile
RSV – Drug Profile
RSV Antivirals – Drug Profile
RSV Artificial Intelligence Drug Discovery Program – Drug Profile
RSV DFC – Drug Profile
RSV Program – Drug Profile
RSV Vaccine – Drug Profile
RSV-276 – Drug Profile
RSV-F005 – Drug Profile
S-337395 – Drug Profile
sisunatovir hydrochloride – Drug Profile
Small Molecule 1 for Respiratory Syncytial Virus Infections – Drug Profile
Small Molecule for Respiratory Syncytial Virus (RSV) Infections – Drug Profile
Small Molecule for Respiratory Syncytial Virus Infections – Drug Profile
Small Molecule to Inhibit RSV F Protein for Respiratory Syncytial Virus Infection – Drug Profile
Small Molecules 2 for Respiratory Syncytial Virus Infections – Drug Profile
Small Molecules for Respiratory Syncytial Virus (RSV) Infections – Drug Profile
Small Molecules for Respiratory Syncytial Virus Infections – Drug Profile
Small Molecules to Inhibit RSV F Protein for Respiratory Syncytial Virus Infection – Drug Profile
SP-0125 – Drug Profile
Syncytial Virus Fusion Inhibitor – Drug Profile
TCB-029 – Drug Profile
TD-214 – Drug Profile
TE-4308 – Drug Profile
TNM-001 – Drug Profile
TP-0591816 – Drug Profile
TRL-3D3 – Drug Profile
TVB-3567 – Drug Profile
TVX-004IP – Drug Profile
verdinexor – Drug Profile
VIS-RSV – Drug Profile
VMT-3 – Drug Profile
VMTX-002 – Drug Profile
VN-0200 – Drug Profile
VPI-251 – Drug Profile
VXB-211 – Drug Profile
VXX-005 – Drug Profile
WLBU-2 – Drug Profile
XW-001 – Drug Profile
YH-009 – Drug Profile
zapnometinib – Drug Profile
zelpultide alfa – Drug Profile
Respiratory Syncytial Virus (RSV) Infections – Dormant Projects
Respiratory Syncytial Virus (RSV) Infections – Discontinued Products
Respiratory Syncytial Virus (RSV) Infections – Product Development Milestones
Featured News & Press Releases
Oct 23, 2022: GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
Oct 18, 2022: Enanta doses first participant in Phase I RSV treatment trial
Oct 07, 2022: Ark Biopharmaceutical presents positive results in phase 3 AIRFLO study of ziresovir in RSV-infected hospitalized infants at 12th International RSV Symposium
Oct 04, 2022: Enanta commences Phase IIb trial of RSV treatment
Oct 04, 2022: Icosavax initiates phase 1 trial of IVX-A12 against RSV and hMPV in older adults
Oct 02, 2022: Enanta Pharmaceuticals announces new preclinical data for its respiratory virology programs to be presented at the 12th International RSV Symposium
Sep 29, 2022: Enanta Pharmaceuticals presents preclinical data for its respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) programs at the 12th International RSV Symposium
Sep 16, 2022: Beyfortus (nirsevimab) recommended for approval in the EU by CHMP for the prevention of RSV lower respiratory tract disease in infants
Aug 26, 2022: Pfizer reports positive Phase III data for bivalent RSV vaccine in adults
Aug 12, 2022: NIHR and Sanofi announce first patient enrolled in large European clinical study to investigate protection against RSV, the leading cause of infant hospitalisation worldwide
Jul 22, 2022: Blue Lake enrols first subject in Phase I RSV vaccine trial
Jun 28, 2022: Icosavax announces positive topline interim phase 1/1b results for VLP vaccine candidate IVX-121 against RSV
Jun 28, 2022: Bavarian Nordic announces grant of PRIME eligibility from the European Medicines Agency for its RSV vaccine candidate for the prevention of respiratory syncytial virus in older adults
Jun 24, 2022: Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by biomedical sciences researchers
Jun 13, 2022: GSK reports positive Phase III data for RSV vaccine in elderly
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
Table 8: Number of Products under Development by Universities/Institutes, 2022
Table 9: Number of Products under Development by Universities/Institutes, 2022 (Contd..1)
Table 10: Products under Development by Companies, 2022
Table 11: Products under Development by Companies, 2022 (Contd..1)
Table 12: Products under Development by Companies, 2022 (Contd..2)
Table 13: Products under Development by Companies, 2022 (Contd..3)
Table 14: Products under Development by Companies, 2022 (Contd..4)
Table 15: Products under Development by Companies, 2022 (Contd..5)
Table 16: Products under Development by Companies, 2022 (Contd..6)
Table 17: Products under Development by Companies, 2022 (Contd..7)
Table 18: Products under Development by Companies, 2022 (Contd..8)
Table 19: Products under Development by Universities/Institutes, 2022
Table 20: Products under Development by Universities/Institutes, 2022 (Contd..1)
Table 21: Number of Products by Stage and Target, 2022
Table 22: Number of Products by Stage and Target, 2022 (Contd..1)
Table 23: Number of Products by Stage and Mechanism of Action, 2022
Table 24: Number of Products by Stage and Route of Administration, 2022
Table 25: Number of Products by Stage and Molecule Type, 2022
Table 26: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Abhelix LLC, 2022
Table 27: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Abivax SA, 2022
Table 28: Respiratory Syncytial Virus (RSV) Infections – Pipeline by ADMA Biologics Inc, 2022
Table 29: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Advac LLC, 2022
Table 30: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Advagene Biopharma Co Ltd, 2022
Table 31: Respiratory Syncytial Virus (RSV) Infections – Pipeline by AIM Vaccine Co Ltd, 2022
Table 32: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Airway Therapeutics Inc, 2022
Table 33: Respiratory Syncytial Virus (RSV) Infections – Pipeline by AlloVir Inc, 2022
Table 34: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Anima Biotech Inc, 2022
Table 35: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Aposense Ltd, 2022
Table 36: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Aridis Pharmaceuticals Inc, 2022
Table 37: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Artificial Cell Technologies Inc, 2022
Table 38: Respiratory Syncytial Virus (RSV) Infections – Pipeline by AstraZeneca Plc, 2022
Table 39: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Atea Pharmaceuticals Inc, 2022
Table 40: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Atriva Therapeutics GmbH, 2022
Table 41: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Auro Vaccines LLC, 2022
Table 42: Respiratory Syncytial Virus (RSV) Infections – Pipeline by AVM Biotechnology LLC, 2022
Table 43: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Bavarian Nordic AS, 2022
Table 44: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Beijing Advaccine Biotechnology Company Ltd, 2022
Table 45: Respiratory Syncytial Virus (RSV) Infections – Pipeline by BioComo Inc, 2022
Table 46: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Biological E Ltd, 2022
Table 47: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Blue Lake Biotechnology Inc, 2022
Table 48: Respiratory Syncytial Virus (RSV) Infections – Pipeline by BlueWillow Biologics Inc, 2022
Table 49: Respiratory Syncytial Virus (RSV) Infections – Pipeline by BravoVax Co Ltd, 2022
Table 50: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Calder Biosciences Inc, 2022
Table 51: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Celestial Therapeutics Inc, 2022
Table 52: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Changchun Bcht Biotechnology Co Ltd, 2022
Table 53: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Chengdu Aoda Biotechnology Co Ltd, 2022
Table 54: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
Table 55: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Cidara Therapeutics Inc, 2022
Table 56: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Clover Biopharmaceuticals Ltd, 2022
Table 57: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Codagenix Inc, 2022
Table 58: Respiratory Syncytial Virus (RSV) Infections – Pipeline by ConserV Bioscience Ltd, 2022
Table 59: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Curevac NV, 2022
Table 60: Respiratory Syncytial Virus (RSV) Infections – Pipeline by CyanVac LLC, 2022
Table 61: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Daiichi Sankyo Co Ltd, 2022
Table 62: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Enanta Pharmaceuticals Inc, 2022
Table 63: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Enyo Pharma SA, 2022
Table 64: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Esperovax Inc, 2022
Table 65: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Eucure (Beijing) Biopharma Co Ltd, 2022
Table 66: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Exopharm Ltd, 2022
Table 67: Respiratory Syncytial Virus (RSV) Infections – Pipeline by F. Hoffmann-La Roche Ltd, 2022
Table 68: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gilead Sciences Inc, 2022
Table 69: Respiratory Syncytial Virus (RSV) Infections – Pipeline by GSK plc, 2022
Table 70: Respiratory Syncytial Virus (RSV) Infections – Pipeline by HanaVax Inc, 2022
Table 71: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Heartland Vaccines LLC, 2022
Table 72: Respiratory Syncytial Virus (RSV) Infections – Pipeline by iBio Inc, 2022
Table 73: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Icosavax Inc, 2022
Table 74: Respiratory Syncytial Virus (RSV) Infections – Pipeline by IDBiologics Inc, 2022
Table 75: Respiratory Syncytial Virus (RSV) Infections – Pipeline by ILiAD Biotechnologies LLC, 2022
Table 76: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunwork Inc, 2022
Table 77: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Imophoron Ltd, 2022
Table 78: Respiratory Syncytial Virus (RSV) Infections – Pipeline by IMV Inc, 2022
Table 79: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Inhalon Biopharma Inc, 2022
Table 80: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Inovio Pharmaceuticals Inc, 2022
Table 81: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Intravacc BV, 2022
Table 82: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Johnson & Johnson, 2022
Table 83: Respiratory Syncytial Virus (RSV) Infections – Pipeline by KARE Biosciences Inc, 2022
Table 84: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Karyopharm Therapeutics Inc, 2022
Table 85: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Kidswell Bio Corp, 2022
Table 86: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Mapp Biopharmaceutical Inc, 2022
Table 87: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Meissa Vaccines Inc, 2022
Table 88: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Merck & Co Inc, 2022
Table 89: Respiratory Syncytial Virus (RSV) Infections – Pipeline by MicroQuin Ltd, 2022
Table 90: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Moderna Inc, 2022
Table 91: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Navigen Inc, 2022
Table 92: Respiratory Syncytial Virus (RSV) Infections – Pipeline by NeuClone Pty Ltd, 2022
Table 93: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Neuracle Science Co Ltd, 2022
Table 94: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Novavax Inc, 2022
Table 95: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Oita University Institute of Advanced Medicine Inc, 2022
Table 96: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Pfizer Inc, 2022
Table 97: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Pinetree Therapeutics Inc, 2022
Table 98: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Pneumagen Ltd, 2022
Table 99: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Poolbeg Pharma Plc, 2022
Table 100: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Prime Vector Technologies GmbH, 2022
Table 101: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Primmune Therapeutics Inc, 2022
Table 102: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Prosit Sole Biotechnology (Beijing) Co Ltd, 2022
Table 103: Respiratory Syncytial Virus (RSV) Infections – Pipeline by ReAlta Life Sciences Inc, 2022
Table 104: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Revelation Biosciences Inc, 2022
Table 105: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Riboscience LLC, 2022
Table 106: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Romark Laboratories LC, 2022
Table 107: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Ruiyang (Suzhou) Biotechnology Co Ltd, 2022
Table 108: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Sagimet Biosciences Inc, 2022
Table 109: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Sanofi, 2022
Table 110: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Sciwind Biosciences Co Ltd, 2022
Table 111: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Shandong Danhong Pharmaceutical Co Ltd, 2022
Table 112: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Shanghai Ark Biopharmaceutical Co Ltd, 2022
Table 113: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Shionogi & Co Ltd, 2022
Table 114: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Sigmovir Biosystems Inc, 2022
Table 115: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Signia Therapeutics, 2022
Table 116: Respiratory Syncytial Virus (RSV) Infections – Pipeline by SK Bioscience Ltd, 2022
Table 117: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
Table 118: Respiratory Syncytial Virus (RSV) Infections – Pipeline by TechnoVax Inc, 2022
Table 119: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Trimunocor Ltd, 2022
Table 120: Respiratory Syncytial Virus (RSV) Infections – Pipeline by TrippBio Inc, 2022
Table 121: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Uvax Bio LLC, 2022
Table 122: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vault Pharma Inc, 2022
Table 123: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vaxart Inc, 2022
Table 124: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vaxxel SAS, 2022
Table 125: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vicebio Ltd, 2022
Table 126: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vir Biotechnology Inc, 2022
Table 127: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Viramatix Sdn Bhd, 2022
Table 128: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Viravaxx AG, 2022
Table 129: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Virometix AG, 2022
Table 130: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Visterra Inc, 2022
Table 131: Respiratory Syncytial Virus (RSV) Infections – Pipeline by VLP Biotech Inc, 2022
Table 132: Respiratory Syncytial Virus (RSV) Infections – Pipeline by X4 Pharmaceuticals Inc, 2022
Table 133: Respiratory Syncytial Virus (RSV) Infections – Pipeline by XBiotech Inc, 2022
Table 134: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2022
Table 135: Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, 2022
Table 136: Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, 2022 (Contd..1)
Table 137: Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, 2022 (Contd..2)
Table 138: Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, 2022 (Contd..3)
Table 139: Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, 2022 (Contd..4)
Table 140: Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, 2022 (Contd..5)
Table 141: Respiratory Syncytial Virus (RSV) Infections – Dormant Projects, 2022 (Contd..6)
Table 142: Respiratory Syncytial Virus (RSV) Infections – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Top 10 Targets, 2022
Figure 5: Number of Products by Stage and Top 10 Targets, 2022
Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 8: Number of Products by Top 10 Routes of Administration, 2022
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 10: Number of Products by Top 10 Molecule Types, 2022
Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings